LimaCorporate
20 Apr_2021

LimaCorporate is proud to announce the first surgery performed in the Stemless Reverse Shoulder System Investigational Device Exemption (IDE) study.

LimaCorporate is proud to announce the first surgery performed in the Stemless Reverse Shoulder System Investigational Device Exemption (IDE) study.
The IDE, approved by FDA last November, allows LimaCorporate evaluate the safety and effectiveness of our Stemless Reverse Shoulder System compared to our Reverse Shoulder System in a randomized, multi-center comparative clinical trial.

This study is an exceptional opportunity for LimaCorporate as there are currently no stemless reverse implants cleared for use by the FDA. LimaCorporate’s IDE study on the Stemless Reverse System, which aims to enroll 200 patients at eight U.S. investigational sites with two-year follow-up, is a pivotal first step to address this unmet need in the U.S. shoulder arthroplasty market.
The IDE Study makes us even more confident about the future: new products, new projects, and activities are growing and taking shape.

Read the full press release here

Other news

28 Mar_2022

LimaCorporate participated in the AAOS annual meeting in Chicago

23 Mar_2022

LimaCorporate introduces L.E.A.R.N. the new platform for a unique medical…

08 Mar_2022

First surgeries completed with patient-specific 3D printed implants produced at…

16 Feb_2022

LimaCorporate'a advanced testing facility received ISO 17025 certification by…

30 Jun_2021

eRSA Course 2021 from now on VuMedi

13 May_2021

1st Surgery using the Trabecular Titanium™ Tibial Plate